SIR-Spheres® Y-90 resin microspheres are approved and indicated in over 40 countries for the treatment of patients with inoperable liver tumours. In addition to its use in metastatic colorectal cancer and hepatocellular carcinoma, a broad range of clinical experience has been gained from patients with liver metastases from neuroendocrine tumours, breast cancer, ocular melanoma and pancreatic cancer, as well as in cholangiocarcinoma.
In the latter, a large international study, called SIRCCA, is evaluating the benefit of applying SIR-Spheres Y-90 resin microspheres prior to systemic chemotherapy. The combination could become a new treatment option for patients with unresectable intrahepatic cholangiocarcinoma (ICC).
Sirtex is broadening its focus to examine the use of SIR-Spheres Y-90 resin microspheres in a number of cancers outside the liver. The first of these studies, called RESIRT, investigated its potential benefit in the treatment of primary renal cell cancer.
de Souza P, Aslan P et al. Phase 1 study of selective internal radiation therapy (SIRT) with yttrium-90 (Y-90) resin microspheres in patients (pts) with renal cell carcinoma (RCC): RESIRT. ESMO Congress, Annals of Oncology 2016; 27 (Suppl 6) Abs: P-803.